Treatment with deutetrabenazine was found to be beneficial for both younger (<55 years) and older (≥55 years) patients with tardive dyskinesia, according to findings from a recently published post hoc analysis.

Deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, is currently approved by the Food and Drug Administration (FDA) for the treatment of tardive dyskinesia in adults. As the incidence of tardive dyskinesia appears to increase with age, researchers looked at data from an ongoing open-label extension study of deutetrabenazine to assess the long-term safety and efficacy of the treatment in younger and older patients with tardive dyskinesia. 

Specifically, the study authors aimed to assess the change from baseline in Abnormal Involuntary Movement Scale (AIMS) score, response rates for ≥50% AIMS improvement, and Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC) treatment success among younger (<55 years) and older (≥55 years) patients.

The study included 124 younger patients and 219 older patients; mean (SD) duration of treatment (740.4 days vs 790.1 days, respectively) and mean±SE total deutetrabenazine dose at week 145 (39.3±1.37 mg/day vs 39.3±1.05 mg/day, respectively) were comparable between the groups. “At week 145, mean±SE changes from baseline in AIMS score were −6.7±0.61 and −6.4±0.47 in younger and older patients, respectively (percent changes of −60.9%±4.06% and −53.8%±3.06%, respectively); the majority of younger and older patients achieved treatment success per CGIC (66% and 76%) and PGIC (both 63%), and 75% of younger and 61% of older patients achieved ≥50% AIMS response,” the study authors reported.   


Continue Reading

As for safety, the treatment was found to be well tolerated in both groups. In younger patients, exposure-adjusted incidence rates for specific adverse events of interest were <0.01 for akathisia, 0.07 for somnolence and sedation, 0.04 for parkinson-like events, and 0.06 for depression. In older patients, the exposure-adjusted incidence rates for these adverse events of interest were 0.02, 0.06, 0.11, and 0.09, respectively.

Based on their findings, the study authors concluded that “deutetrabenazine treatment was associated with sustained improvements in AIMS score and was well tolerated in both younger and older TD patients.”

Reference

Sajatovic M, Wilhelm A, Finkbeiner S, et al. Long-term safety and efficacy of deutetrabenazine in younger and older patients with tardive dyskinesia. Neurology. April 2020, 94 (15 Supplement) 2003.

This article originally appeared on MPR